فلتر
خيارات المدونة
أغلق

اتلابوتازون

الشركة: ATLAS VETERINAIRE
(PBZ) is a nonsteroidal anti-inflammatory drug widely used in veterinary medicine, more particularly in the horse.
90.00 ر.ق.
- +
 
COMPOSITION
Phenylbutazone…                                                                     20.00 g
Excipient q.s.p. ……… .. ……………………………………………………………… ....… 100 ml
ARMACEUTICAL PROPERTIES
Phenylbutazone (PBZ) is a nonsteroidal anti-inflammatory drug widely used in veterinary medicine,
more particularly in the horse.
The PBZ is endowed with powerful anti-inflammatory, antipyretic and analgesic activities.
PBZ is well absorbed via the digestive in monogastrics.
However, its bioavailability is greatly reduced by taking food.
In the blood, PBZ binds highly to plasma proteins, which limits consequently its tissue diffusion.
Its half-life is of the order of 6 hours in horse.
PBZ undergoes intense metabolism in the liver generating a very active metabolite (oxyphenbutazone)
especially in horses.
PBZ and its metabolites are partially eliminated in the urine.
TARGET SPECIES
Equidae not intended for slaughter.
INDICATIONS
Treatment of inflammatory and painful phenomena in the target species.
The product is particularly indicated in the following cases:
Arthritis, arthritis, tendonitis, tendinosynovitis, bursitis,
articular and muscular rheumatism, congestive processes, hyperthermia, heat stroke,
inflammatory complications of conditions various traumatic or microbial.
ADMINISTRATION AND DOSAGE
Slow and strict intravenous use. The dosage is 2.2 to 4.4 mg of phenylbutazone / Kg of PV,
corresponding to 1.1 to 2.2 ml of
ATLABUTAZONE Injection per 100 kg of bodyweight,
per day for a maximum of 5 days.
Treatment can be continued with the use of the oral form. The maximum dose is 4 g per day per adult animal.
 PHARMACEUTICAL PROPERTIES
Phenylbutazone (PBZ) is a nonsteroidal anti-inflammatory drug widely used in
veterinary medicine, more particularly in the horse. The PBZ is endowed with powerful
anti-inflammatory, antipyretic and analgesic activities. PBZ is well absorbed via the
digestive in monogastrics. However, its bioavailability is greatly reduced by taking
food. In the blood, PBZ binds highly to plasma proteins, which limits
consequently its tissue diffusion. Its half-life is of the order of 6 hours in
horse. PBZ undergoes intense metabolism in the liver generating a very active metabolite
(oxyphenbutazone) especially in horses. PBZ and its metabolites are partially eliminated
in the urine.
TARGET SPECIES
Equidae not intended for slaughter.
INDICATIONS
Treatment of inflammatory and painful phenomena in the target species. The product is
particularly indicated in the following cases:
Arthritis, arthritis, tendonitis, tendinosynovitis, bursitis, articular and muscular rheumatism,
congestive processes, hyperthermia, heat stroke, inflammatory complications of conditions
various traumatic or microbial.
ADMINISTRATION AND DOSAGE
Slow and strict intravenous use.
The dosage is 2.2 to 4.4 mg of phenylbutazone / Kg of PV, corresponding to 1.1 to 2.2 ml
of ATLABUTAZONE Injection per 100 kg of bodyweight, per day for a maximum of 5 days.
Treatment can be continued with the use of the oral form.
The maximum dose is 4 g per day per adult animal.
CONTRAINDICATIONS AND INTERACTIONS
- Hepatic, renal or cardiac disorders.
- Haematological history (dyscrasia).
- Do not administer to animals whose meat is intended for human consumption
- Do not administer to animals with digestive tract ulcers
- Hypersensitivity to phenylbutazone or one of the excipients
- For safety reasons, it is not recommended to use PBZ in females during the first
third and finally gestation.
Interactions are possible with the following substances:
- Coumarin derivatives such as warfarin,
- Penicillin G,
- Furosemide and other diuretics,
- Corticosteroids.
Associations not recommended:
- Other NSAIDs (including salicylates in high doses): increased ulcerogenic risk and
digestive haemorrhage (additive synergy),
- Heparin (parenteral route): increased risk of bleeding,
- Hypoglycaemic sulfonamides: increase in the hypoglycaemic effect of sulfonamides
(displacement of their binding to plasma proteins and / or decrease in their elimination).
Combinations requiring precautions for use:
-Pentoxifylline: increased risk of bleeding.
SIDE EFFECTS
The side effects that may be observed are the following:
- Local reactions; risk of thrombophlebitis
- Gastrointestinal disorders,
- Decrease in plasma levels of thyroid hormones,
- Kidney damage up to papillary necrosis.
- Bleeding, but the incidence of these symptoms is very low.
PRECAUTIONS FOR USE
- Intravenous injections should be given slowly.
- Avoid bubbling the blood into the syringe:
- Respect the dose, especially in weak or dehydrated subjects.
- As a precaution, use gloves when handling
- Do not smoke or eat while using the product.
- The product must always be handled with great care to reduce the risk of accidental self-injection or contact with the skin.
- In the event of accidental contact with the skin, wash immediately with water.
- In case of accidental self-injection, seek medical advice immediately and
show package leaflet or label.
- Keep the product out of the reach of children.
TIMEOUT
Do not use in animals whose meat is intended for human consumption
STORAGE CONDITIONS
Product stable for 2 years in the original packaging, protected from light and at a temperature
≤ 25 ° C.
Stability after opening: 4 weeks
PHARMACEUTICAL FORM AND PRESENTATION:
50 and 100 ml bottle
 
 
 
COMPOSITION
Phenylbutazone…                                                                     20.00 g
Excipient q.s.p. ……… .. ……………………………………………………………… ....… 100 ml
ARMACEUTICAL PROPERTIES
Phenylbutazone (PBZ) is a nonsteroidal anti-inflammatory drug widely used in veterinary medicine,
more particularly in the horse.
The PBZ is endowed with powerful anti-inflammatory, antipyretic and analgesic activities.
PBZ is well absorbed via the digestive in monogastrics.
However, its bioavailability is greatly reduced by taking food.
In the blood, PBZ binds highly to plasma proteins, which limits consequently its tissue diffusion.
Its half-life is of the order of 6 hours in horse.
PBZ undergoes intense metabolism in the liver generating a very active metabolite (oxyphenbutazone)
especially in horses.
PBZ and its metabolites are partially eliminated in the urine.
TARGET SPECIES
Equidae not intended for slaughter.
INDICATIONS
Treatment of inflammatory and painful phenomena in the target species.
The product is particularly indicated in the following cases:
Arthritis, arthritis, tendonitis, tendinosynovitis, bursitis,
articular and muscular rheumatism, congestive processes, hyperthermia, heat stroke,
inflammatory complications of conditions various traumatic or microbial.
ADMINISTRATION AND DOSAGE
Slow and strict intravenous use. The dosage is 2.2 to 4.4 mg of phenylbutazone / Kg of PV,
corresponding to 1.1 to 2.2 ml of
ATLABUTAZONE Injection per 100 kg of bodyweight,
per day for a maximum of 5 days.
Treatment can be continued with the use of the oral form. The maximum dose is 4 g per day per adult animal.
 PHARMACEUTICAL PROPERTIES
Phenylbutazone (PBZ) is a nonsteroidal anti-inflammatory drug widely used in
veterinary medicine, more particularly in the horse. The PBZ is endowed with powerful
anti-inflammatory, antipyretic and analgesic activities. PBZ is well absorbed via the
digestive in monogastrics. However, its bioavailability is greatly reduced by taking
food. In the blood, PBZ binds highly to plasma proteins, which limits
consequently its tissue diffusion. Its half-life is of the order of 6 hours in
horse. PBZ undergoes intense metabolism in the liver generating a very active metabolite
(oxyphenbutazone) especially in horses. PBZ and its metabolites are partially eliminated
in the urine.
TARGET SPECIES
Equidae not intended for slaughter.
INDICATIONS
Treatment of inflammatory and painful phenomena in the target species. The product is
particularly indicated in the following cases:
Arthritis, arthritis, tendonitis, tendinosynovitis, bursitis, articular and muscular rheumatism,
congestive processes, hyperthermia, heat stroke, inflammatory complications of conditions
various traumatic or microbial.
ADMINISTRATION AND DOSAGE
Slow and strict intravenous use.
The dosage is 2.2 to 4.4 mg of phenylbutazone / Kg of PV, corresponding to 1.1 to 2.2 ml
of ATLABUTAZONE Injection per 100 kg of bodyweight, per day for a maximum of 5 days.
Treatment can be continued with the use of the oral form.
The maximum dose is 4 g per day per adult animal.
CONTRAINDICATIONS AND INTERACTIONS
- Hepatic, renal or cardiac disorders.
- Haematological history (dyscrasia).
- Do not administer to animals whose meat is intended for human consumption
- Do not administer to animals with digestive tract ulcers
- Hypersensitivity to phenylbutazone or one of the excipients
- For safety reasons, it is not recommended to use PBZ in females during the first
third and finally gestation.
Interactions are possible with the following substances:
- Coumarin derivatives such as warfarin,
- Penicillin G,
- Furosemide and other diuretics,
- Corticosteroids.
Associations not recommended:
- Other NSAIDs (including salicylates in high doses): increased ulcerogenic risk and
digestive haemorrhage (additive synergy),
- Heparin (parenteral route): increased risk of bleeding,
- Hypoglycaemic sulfonamides: increase in the hypoglycaemic effect of sulfonamides
(displacement of their binding to plasma proteins and / or decrease in their elimination).
Combinations requiring precautions for use:
-Pentoxifylline: increased risk of bleeding.
SIDE EFFECTS
The side effects that may be observed are the following:
- Local reactions; risk of thrombophlebitis
- Gastrointestinal disorders,
- Decrease in plasma levels of thyroid hormones,
- Kidney damage up to papillary necrosis.
- Bleeding, but the incidence of these symptoms is very low.
PRECAUTIONS FOR USE
- Intravenous injections should be given slowly.
- Avoid bubbling the blood into the syringe:
- Respect the dose, especially in weak or dehydrated subjects.
- As a precaution, use gloves when handling
- Do not smoke or eat while using the product.
- The product must always be handled with great care to reduce the risk of accidental self-injection or contact with the skin.
- In the event of accidental contact with the skin, wash immediately with water.
- In case of accidental self-injection, seek medical advice immediately and
show package leaflet or label.
- Keep the product out of the reach of children.
TIMEOUT
Do not use in animals whose meat is intended for human consumption
STORAGE CONDITIONS
Product stable for 2 years in the original packaging, protected from light and at a temperature
≤ 25 ° C.
Stability after opening: 4 weeks
PHARMACEUTICAL FORM AND PRESENTATION:
50 and 100 ml bottle
 
 
مواصفات المنتج
الأدوية مضاد للالتهاب
كتابة التقييم الخاص بك
  • يمكن للمستخدمين المسجلين فقط التقييم
*
*
  • سىء
  • ممتاز
*
*
*
مواصفات المنتج
الأدوية مضاد للالتهاب
علامات المنتج